http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112353808-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_615bd7f2c0a8cad77f76b71d1fb9f42a |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-725 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K131-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-725 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7048 |
| filingDate | 2020-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8f77ccaeac5b207ac97818fb67d2b167 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a324b5acd21842859e94cd70222c43a1 |
| publicationDate | 2021-02-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-112353808-A |
| titleOfInvention | Application of spinosin in the preparation of drugs for reducing inflammation and inhibiting Alzheimer's disease |
| abstract | The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to the application of spinosin in the preparation of a medicine for alleviating inflammation and inhibiting AD. The application of spinosin in the preparation of drugs for preventing, improving, treating or anti-AD. Based on two aspects, the mechanism of spinosin's inhibitory effect on AD was described. On the one hand, Aβ is produced too much, accumulates in the brain, and finally forms a class, and the ability of learning, memory and cognition is significantly weakened or even completely lost, which is AD disease. Spinosin can significantly slow down Aβ aggregation, slowing down or avoiding the occurrence of AD. On the other hand, spinosin reduced the overexpression of COX-2 protein triggered by Aβ; inhibited the release of inflammatory factors; reduced apoptosis; and finally improved the learning and memory impairments damaged by Aβ 25-35 , thereby alleviating AD symptoms. |
| priorityDate | 2020-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 66.